Program
Enavogliflozin
Also written as “DWP16001”, “DWP16001 0.3mg” and “DWP16001 Amg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetic Nephropathies, led by Daewoong Pharmaceutical.
Furthest: phase 3, since Nov 12, 202025 company-led studies, 8 open or runningNext primary completion: Nov 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daewoong Pharmaceutical | 258 open or running | phase 3since Nov 12, 2020 | Nov 29, 2017 | Nov 2027phase 3 · NCT07619833 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Nov 29, 2017.
- Jan 9, 20222 phase 3 studies in Diabetes Mellitus, Type 2NCT05376969, NCT05376930
- Jun 8, 2022Phase 1 study in HealthyNCT05414591 · 38 enrolled · Korea, Republic of
- Jul 5, 2022Phase 1 study in Healthy VolunteersNCT05465668 · 43 enrolled · Korea, Republic of
- Jul 12, 2022Phase 3 study in Diabetes Mellitus, Type 2NCT05466643 · 240 planned · Korea, Republic of
- Aug 12, 2022Phase 1 study in HealthyNCT05500898 · 53 enrolled
- Aug 16, 2022Phase 3 study in Diabetes MellitusNCT05505994 · 340 enrolled · China
- Jan 17, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05737771 · 40 enrolled · Korea, Republic of
- Feb 8, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05747664 · 24 planned · Korea, Republic of
- Mar 21, 2023Phase 1 study in HealthyNCT05797922 · 32 planned · Korea, Republic of
- Nov 10, 2023Phase 3 study in Diabetes Mellitus, Type 2NCT06141980 · 134 planned
- Sep 10, 2024Phase 3 study in Type 2 Diabetic NephropathyNCT06606093 · 348 planned · Korea, Republic of
- Oct 11, 2024Phase 1 study in HealthyNCT06644404 · 34 planned · Korea, Republic of
- Jul 29, 2025Phase 1 study in HealthyNCT07213310 · 18 enrolled · South Korea
- May 26, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07619833 · 510 planned · South Korea
Ahead
- Nov 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07619833
TargetBeta
SLC5A2 →read by rule
“The primary objective of this study is to investigate the effect of enavogliflozin, an Sodium-glucose transporter 2 (SGLT2) inhibitor, compared with placebo on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy.”study text, by rule · the study
Other programs on SLC5A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| empagliflozinrule | Boehringer Ingelheim | phase 4 | 142 |
| dapagliflozin | AstraZeneca | phase 4 | 133 |
| ertugliflozinrule | Merck | phase 4 | 22 |
| vicadrostat | Boehringer Ingelheim | phase 3 | 16 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07619833Diabetes Mellitus, Type 2 · South Korea | 3 | Not yet recruiting | Nov 2027 | 510 |
| NCT07213310Healthy · South Korea | 1 | Completed | Jan 7, 2026 | 18 |
| NCT06644404Healthy · Korea, Republic of | 1 | Not yet recruiting | Dec 3, 2024 | 34 |
| NCT06606093Type 2 Diabetic Nephropathy · Korea, Republic of | 3 | Not yet recruiting | Sep 1, 2026 | 348 |
| NCT06141980Diabetes Mellitus, Type 2 | 3 | Not yet recruiting | Sep 2025 | 134 |
| NCT05797922Healthy · Korea, Republic of | 1 | Recruiting | May 31, 2023 | 32 |
| NCT05747664Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Recruiting | Apr 30, 2024 | 24 |
| NCT05737771Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | UNKNOWN | Mar 31, 2023 | 40 |
| NCT05505994Diabetes Mellitus · China | 3 | Active, not recruiting | Feb 26, 2024 | 340 |
| NCT05500898Healthy | 1 | UNKNOWN | Oct 31, 2022 | 53 |
| NCT05466643Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Recruiting | Sep 30, 2024 | 240 |
| NCT05465668Healthy Volunteers · Korea, Republic of | 1 | Completed | Aug 16, 2022 | 43 |
| NCT05414591Healthy · Korea, Republic of | 1 | Completed | Aug 1, 2021 | 38 |
| NCT05321732Healthy Volunteers · Korea, Republic of | 1 | UNKNOWN | Aug 2022 | 24 |
| NCT05207176Healthy | 1 | UNKNOWN | Apr 8, 2022 | 24 |
| NCT05376969Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | May 16, 2022 | 159 |
| NCT05376930Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | May 31, 2022 | 63 |
| NCT05192395Healthy · Korea, Republic of | 1 | Completed | May 24, 2022 | 37 |
| NCT04654390Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | Dec 17, 2021 | 270 |
| NCT04632862Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | Nov 25, 2021 | 140 |
| NCT04343547Healthy · Korea, Republic of | 1 | UNKNOWN | Jul 2020 | 34 |
| NCT04221399Type2 Diabetes | 1 | UNKNOWN | Aug 2020 | 35 |
| NCT04064073Healthy · Korea, Republic of | 1 | Completed | Nov 20, 2019 | 34 |
| NCT04014023Diabetes Mellitus, Type 2 · Korea, Republic of | 2 | UNKNOWN | Mar 2020 | 196 |
| NCT03364985Healthy · Korea, Republic of | 1 | Completed | May 21, 2019 | 123 |
How it is read
Names in the registry
- “DWP16001”, 18 entries
- “DWP16001 0.3mg”, 3 entries
- “DWP16001 Amg”, 2 entries
- “DWP16001 0.3 mg”, 1 entry
- “DWP16001 Drug A”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 12 studies
- Diabetic Nephropathies, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.